Conference Call with Akums Drugs & Pharmaceuticals Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Akums Drugs & Pharmaceuticals announced Q1FY26 results Total income: Rs 1,051 crore compared to Rs 1,026 crore during Q1FY25, EBITDA: Rs 156 crore compared to Rs 111 crore during Q1FY25, EBITDA Margin: 14.8% for Q1FY26. PAT: Rs 65 crore compared to Rs 44 crore during Q1FY25, PAT Margin: 6.2% for Q1FY26. Sanjeev Jain, Managing Director, said: " This date marks just over one year since we got listed. We continue to work towards strengthening the organization with a focus on long term growth. Our commitment to becoming a global CDMO player remains steadfast. The recent filings along with the planned global approvals of other facilities are setting up us in that endeavor. " Sandeep Jain, Managing Director, said: "We continue to deliver strong performance despite the industry headwinds of decreasing API prices and muted volume growth. With a sustained focus on R&D;, we have been able to deliver robust growth. Achieving 1,000 DCGI approvals is a key milestone that stands out Akums from its peers, allowing Akums to offer margin accretive differentiated offerings. We remain focused on strengthening our CDMO leadership, scaling high-value capabilities, and driving operational excellence. Backed by a strong pipeline and prudent capital allocation, we are well-positioned to deliver sustainable and profitable growth in the years ahead. " Result PDF